.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Covington
Harvard Business School
Cerilliant
Moodys
Farmers Insurance
Cantor Fitzgerald
Daiichi Sankyo
UBS
Johnson and Johnson

Generated: September 24, 2017

DrugPatentWatch Database Preview

GIAZO Drug Profile

« Back to Dashboard

What is the patent landscape for Giazo, and what generic Giazo alternatives are available?

Giazo is a drug marketed by Valeant Pharms Intl and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-seven patent family members in nineteen countries.

The generic ingredient in GIAZO is balsalazide disodium. There are ten drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the balsalazide disodium profile page.

Summary for Tradename: GIAZO

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list36
Patent Applications: see list2,253
Drug Prices:see details
DailyMed Link:GIAZO at DailyMed

Pharmacology for Tradename: GIAZO

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Intl
GIAZO
balsalazide disodium
TABLET;ORAL022205-001Feb 3, 2012ABRXYesYes► Subscribe► Subscribe ► Subscribe
Valeant Pharms Intl
GIAZO
balsalazide disodium
TABLET;ORAL022205-001Feb 3, 2012ABRXYesYes► Subscribe► Subscribe ► Subscribe
Valeant Pharms Intl
GIAZO
balsalazide disodium
TABLET;ORAL022205-001Feb 3, 2012ABRXYesYes► Subscribe► Subscribe ► Subscribe
Valeant Pharms Intl
GIAZO
balsalazide disodium
TABLET;ORAL022205-001Feb 3, 2012ABRXYesYes► Subscribe► Subscribe ► Subscribe
Valeant Pharms Intl
GIAZO
balsalazide disodium
TABLET;ORAL022205-001Feb 3, 2012ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for GIAZO

Drugname Dosage Strength RLD Submissiondate
balsalazide disodiumTablets1.1 gGiazo11/5/2013

Non-Orange Book Patents for Tradename: GIAZO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,921,344Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: GIAZO

Country Document Number Estimated Expiration
European Patent Office2529729► Subscribe
Japan2001519782► Subscribe
New Zealand593132► Subscribe
China105267226► Subscribe
Japan2009506067► Subscribe
World Intellectual Property Organization (WIPO)2008063211► Subscribe
European Patent Office2096912► Subscribe
Hungary0000850► Subscribe
Mexico2008002283► Subscribe
South Korea20090118906► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Citi
Cipla
UBS
Farmers Insurance
Fuji
Fish and Richardson
Healthtrust
US Department of Justice
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot